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Diabetes mellitus is one of the most common diseases, with a 200% predicted increase in 
prevalence over the next several decades (Kadoi, 2010).  With a known increase in 
perioperative risk, diabetic patients present with multiple comorbidities that must be 
considered when adopting an anesthetic plan (Kadoi, 2010).  One of the most common 
complications affecting approximately 50% of patients, is gastroparesis resulting from 
the development of diabetic autonomic neuropathy.  Gastroparesis places the diabetic 
patient at an increased risk of aspiration and also postoperative nausea and vomiting 
(PONV).  Dexamethasone is a glucocorticoid that is one of the most common 
prophylactic antiemetics used to prevent PONV.  Dexamethasone has been associated 
with an increase in blood glucose levels which can be detrimental to the diabetic surgical 
patient (Shaikh et al., 2016).  The purpose of this systematic review was to investigate the 
current literature and examine the impact of dexamethasone on blood glucose levels in 
the adult diabetic surgical patient when used in the prevention of PONV.  A 
comprehensive literature review was completed using CINAHL and PubMed databases.  
The physiology and perioperative management of diabetes and PONV, along with the 
pharmacodynamics of dexamethasone was reviewed.  Eligible studies were chosen based 
on guidance from the PRISMA theoretical framework.  Study analysis was completed by 
constructing study specific and data outcome tables.  Critical appraisal of individual 
RCTs was conducted utilizing the Critical Appraisal Skills Programme (CASP) checklist.  
A cross study analysis table was also developed comparing the results of all eligible 




dexamethasone 8mg IV was associated with an increase in perioperative blood glucose 
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The Use of Dexamethasone in the Adult Diabetic Surgical Population for the 
Prevention of Postoperative Nausea and Vomiting: A Systematic Review  
Background/Statement of the Problem 
 Diabetic patients present to surgery with independent risk factors.  Patients 
with hyperglycemia during the surgical period are at a greater risk for electrolyte 
imbalances, dehydration, increased risk of infection, fluid shifts, compromised wound 
healing, and ketoacidosis (Joshi et al., 2010).  Diabetic patients often have other 
associated comorbidities resulting from chronic inadequate blood glucose control.  
Microvascular changes are often seen in the retinal and renal vessels, impacting sight and 
kidney function.  Peripheral neuropathy and increased infection risk also need to be taken 
into consideration during the perioperative period.  One of the most severe complications 
associated with diabetes is the presence of autonomic neuropathy.  Diabetic autonomic 
neuropathy is a condition characterized by damage to small autonomic nerve fibers 
resulting in greater decline in blood pressure and increased need of vasopressors in the 
perioperative period.  Other symptoms accompanying diabetic autonomic neuropathy 
include hypotension associated with position changes, impotence, diarrhea, sweating 
abnormalities and delayed gastric emptying.  Diabetic patients with autonomic 
neuropathy are at an elevated risk for postoperative nausea and vomiting (PONV) and 
gastric aspiration due to gastroparesis (Miller et al., 2015). 
 PONV occur in 20% to 40% of all surgical patients and is the second most 
common complaint secondary to pain (Cao et al., 2017).  The occurrence of PONV can 
delay recovery, prolong discharge, and result in unanticipated hospital admission.  It also 
places the patient at a higher risk of developing pulmonary aspiration, electrolyte 
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imbalances, wound dehiscence, and dehydration.  All of these complications result in 
increased distress on the patient and increased medical costs (Shaikh et al., 2016). 
Despite a considerable amount of research conducted and strategies developed, 
there has not been a consensus on an optimal regimen to treat PONV.  However, there 
has been emphasis in literature and practice on the anticipatory rather than reactionary 
treatment.  Dexamethasone is a glucocorticoid steroid that is one of the most common 
anticipatory antiemetics used.  The use of dexamethasone is associated with potential 
risks including impaired wound healing, increased blood glucose levels, and an increase 
risk of infection (Miller et al., 2015).  These risk factors make its use in the diabetic 
population controversial.  Therefore, this study examines the impact of dexamethasone 
on blood glucose levels in the adult diabetic surgical patient when used in the prevention 
of PONV. 
Next, a literature review will be presented.  
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Literature Review 
A literature review was preformed to examine information about the use of 
dexamethasone in diabetic patients to prevent PONV.  Databases searched were PubMed, 
Medline, CINAHL, and google scholar.  Search words included dexamethasone, diabetes, 
and postoperative nausea and vomiting.  Randomized control trials, evidence-based 
reviews, and guidelines were included in this literature review.  
Diabetes Mellitus 
In 2015, 30.3 million Americans had diabetes with an additional 1.5 million new 
cases added each year (ADA, 2015).  Diabetes was the seventh leading cause of death in 
2015 (ADA, 2015) with a mortality rate three times higher than the average population 
(Kadoi, 2010).  Although, a diagnosis of diabetes is not an independent risk factor for the 
development of PONV, approximately 50% of diabetic patients suffer from gastroparesis 
or delayed gastric emptying.  This delayed emptying can result in a cascade of injurious 
events in which the increase in gastric volume can contribute to the development of 
symptoms of nausea and vomiting, but also induce aspiration of gastric contents during 
induction of anesthesia (Kadoi, 2010).  With aspiration being the number one cause of 
airway-related mortality for anesthesia providers, a probable increase in gastric contents 
of diabetic patients prompts serious consideration and planning during the perioperative 
period (Robinson & Davidson, 2014). 
Pathophysiology.  Diabetes Mellitus (DM) is a group of disorders sharing the 
clinical feature of absolute or relative lack of insulin.  DM is diagnosed with a fasting 
blood glucose (BG) of greater than 110 mg/dL (6.1 mmol/L) (Miller et al, 2015).  
Impaired glucose tolerance can be diagnosed with a fasting BG of 109 mg/dL – 100 
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mg/dL (6.1 mmol/L – 5.5 mmol/L) (Miller et al, 2015).  DM is characterized by multiple 
metabolic abnormalities that can result in microvascular lesions and long-term end-organ 
damage.  The term “diabetes” can account for two different diseases that share the same 
complication of end-organ damage: type 1 and type 2 (Miller et al, 2015). 
Type 1 DM occurs when a patient is unable to produce insulin.  Insulin is 
produced in the pancreas by beta cells; these cells are susceptible to viral infections 
and/or autoimmune disorders.  Cellular metabolism is dependent on glucose metabolism 
which is fielded by insulin.  Lack of insulin production not only results in high glucose 
levels but it also forces the body into generating alternative fuel.  The alternative fuel 
source can be derived from the breakdown of fats and proteins.  An increase in keto acid 
byproducts from the destruction of fats and proteins can result in the development of 
ketoacidosis and lead to diabetic coma and death (Miller et al, 2015).   
Type 2 DM results when there is a decreased response to insulin at the target 
tissues.  Type 2 diabetics account for 90 to 95% of all cases of diabetes.  This disease has 
a gradual onset and generally develops after the age of 30.  The greatest risk factor for the 
development of type 2 DM is obesity.  The direct mechanism in which type 2 DM is 
acquired is uncertain, however, it has been suggested that obese patients have fewer 
insulin receptors.  Another hypothesis suggests that due to increase lipid concentration, 
signaling pathways between insulin and its receptors are interrupted (Hall, 2011). 
Perioperative Blood Glucose Management.  There is a lack of clear evidence to 
suggest the optimal intraoperative glucose level, thus it remains unknown.  The Society 
for Ambulatory Anesthesia (SAMBA) published a consensus statement on diabetic 
perioperative glucose management based on hospitalized surgical patient data and also 
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the joint consensus statement from the American Association of Clinical 
Endocrinologists (AACE) and American Diabetes Association (ADA) in 2010.  SAMBA 
recommends an individualized approach for glucose control; duration of surgery, degree 
of surgical invasiveness, anesthetic choice, and expected time until resumption of 
antidiabetic therapy must be considered.  For the well-controlled diabetic patient, 
intraoperative BG levels should be maintained <180 mg/dL (10.0 mmol/L).  Poorly 
controlled diabetics need a more modest approach to glucose control.  Patients with 
chronically elevated BG levels should be maintained around their preoperative baseline.  
Chronic hyperglycemia results in the alteration of autoregulatory mechanisms.  
Adaptations in the release of norepinephrine, epinephrine, cortisol, growth hormone, and 
pancreatic polypeptides can occur.  An acute drop in BG can result in symptomatic 
hypoglycemia and organ dysfunction due to the body being accustomed to 
hyperglycemia.  An increase in the oxidative stress response can also occur.  Such acute 
fluctuations in the chronic hyperglycemic patient may increase morbidity and mortality, 
perioperatively (Joshi et al., 2010).  
Surgical Stress Response.  Under times of stress and surgical stimulation, the 
body responds to this stimulus with a wide range of endocrine, biochemical, and 
metabolic reactions.  The degree of response is in direct proportion to the stimuli.  This 
response is called the surgical stress response and although general anesthesia abolishes 
awareness and perception, it does not suppress the coordinated response from the 
autonomic nervous system and the neuro-endocrinal hormone system.  These systems 
release a variety of catabolic and anabolic hormones triggering a hypermetabolic state.  
This state is generally well tolerated amongst healthy patients, however, in patient 
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populations with coronary artery disease, hypertension, aneurysmal disease, diabetes, 
liver or renal disease these hypermetabolic changes increase mortality (Singh, 2003).  
 One of the main reactions to the stress response is stimulation of the 
hypothalamus resulting in secretion of ACTH, which initiates a sudden increase of 
cortisol, the main endogenous glucocorticoid.  Cortisol has the ability to stimulate the 
mobilization of amino acids to be converted into glucose, a process known as 
gluconeogenesis (Singh, 2003).  Cortisol also decreases glucose utilization by the cell, 
further increasing hyperglycemia.  Singh (2003) reports blood glucose levels can increase 
by 50% from the preoperative normal. 
 To further increase hyperglycemia, Desborough (2000) describes an “insulin 
resistant” state that also occurs during the perioperative phase.  Insulin levels can 
decrease after induction of anesthesia due to failure of secretion by beta cells of the 
pancreas and also failure of cellular response to insulin (Desborough, 2000).  Another 
contribution to the hyperglycemic response to major surgery is the transient increase in 
glucagon.  Glucagon is a hormone produced by the alpha cells of the pancreas, which 
promotes glycogenolysis, the breakdown of glycogen to glucose.  Glucagon also 
promotes gluconeogenesis, further increasing blood glucose levels (Desborough, 2000) 
 Regional anesthesia uses local anesthetics to produce a neural blockade which has 
direct influence on the metabolic and endocrinal response.  The inhibition of afferent and 
efferent neural pathways prevents surgical stimulus from reaching the central nervous 
system (Singh, 2003).  Singh (2003) reports that a neuraxial blockade from T4 to S4 
prevents the cortisol response during lower abdominal surgeries.  In order to prevent the 
insulin and glucagon response, a higher blockade from T2 to T6 is required, however, 
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this level of blockade is often contradicted due detrimental alterations in cardiac function 
that can occur (Singh, 2003). 
 Diabetic patients have been hypothesized to be in a chronic inflammatory state 
when compared to nondiabetic healthy patients (Lin & Gletsu-Miller, 2012).  This 
chronic inflammatory state can be potentiated under surgical stress, leading to deleterious 
outcomes (Lin & Gletsu-Miller, 2012).  A study done by Lin and Gletsu-Miller (2012) 
aimed to investigate the differences in the surgical stress response between diabetic and 
nondiabetic patients undergoing laparoscopic Roux-en-Y gastric bypass by measuring 
inflammatory cytokine levels.  The study measured cytokine levels (IL-6, IL-10, and IL-
18) preoperatively and immediately after surgery in 39 morbidly obese patients (nine 
with type 2 diabetes) and eight non-obese, normoglycemic patients (Lin & Gletsu-Miller, 
2012).  The results demonstrated an overall increase in in cytokine expression in the 
diabetic and morbidly obese patients by several folds in comparison to the non-obese, 
normoglycemic groups.  At baseline, a higher IL-6 level was exhibited in the morbidly 
obese group compared to the non-obese group (5.7 ± 1.3 pg/ml and 2.7 ± 0.6 pg/ml, 
respectively, p < 0.05).  The IL-6 response was induced highest amongst the diabetic, 
obese group (78.9 ± 12.3 pg/ml); a modest response in the non-diabetic, obese group 
(61.0 ± 5 pg/ml); and the lowest response in the non-obese group (36.3 ± 7.2 pg/ml) (p < 
0.01).  Consistent findings occurred with the IL-10 response.  At baseline, the IL-10 
levels were 1.5 ± 0.4 pg/ml, 1.2 ± 0.3, and 1.3 ± 0.3 pg/ml for non-diabetic, obese; 
diabetic obese; and non-obese groups, respectively.  The greatest IL-10 response 
occurred in the obese, diabetic group (65.8 ± 1.9pg/ml, p < 0.001).  The non-diabetic, 
obese group and non-obese group levels were not significant but did increase post-
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operatively (15.1 ± 5.0 pg/ml and 8.5 ± 2.7pg/ml).  It was found that preoperative IL-18 
levels were significantly increased in the diabetic, obese patients (450.6 ± 56 pg/ml, p < 
0.01) compared to the non-diabetic, obese group (297.8 ± 19pg/ml) and non-obese group 
(286.6 ± 17pg/ml).  However, post-operatively there was almost zero change to all three 
groups (diabetic obese: 457.9 ± 64 pg/ml; non-diabetic obese: 300 ± 26 pg/ml; non-
obese: 271 ± 31 pg/ml) (Lin & Gletsu-Miller, 2012).   These results demonstrate a clear 
increase in the surgical stress response in diabetic patients.  An excessive or perpetual 
inflammatory response can overwhelm the patient’s compensatory mechanisms, 
potentiating multi-organ failure leading to demise (Lin & Gletsu-Miller, 2012).  Careful 
consideration must be made when choosing an anesthetic plan for a diabetic patient; the 
use of an additional glucocorticoid, dexamethasone, can further increase cortisol levels 
thus contributing to an increased surgical stress response. 
Perioperative Risks.  Perioperative risk factors vary based on individual health 
practices and lifestyle choices.  Diabetic patients undergoing surgery are at risk for 
complications associated with end-organ dysfunction: renal insufficiency, cardiovascular 
deterioration, joint and collagen tissue irregularities, neuropathies and inadequate 
production of granulocytes (Grossman & Porth, 2014). 
In a study done by Ghildiyal et al. (2016), perioperative hyperglycemia and the 
incidence of postoperative infection was examined.  The researchers conducted a 
prospective study including 101 patients undergoing a variety of procedures.  Random 
blood sugars were taken preoperatively, intraoperatively, and postoperatively.  A 30-day 
postoperative follow-up was done evaluating for surgical wound infection, septicemia, 
and urinary tract infections.  Fifty-seven out of the 101 patients did have an incidence of 
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hyperglycemia.  The hyperglycemic patients developed infections at a rate of 26.3% 
(15/57) compared to normoglycemic patients at 4.5% (2/44) (Ghildiyal et al., 2016). 
In a retrospective cohort study performed by Guvener et al. (2002) aimed to 
examine perioperative hyperglycemia and the incidence of postoperative infection in 
diabetic patients undergoing coronary artery bypass grafting.  The researchers examined 
1090 adult charts, 400 out of 1090 patients had type 2 diabetes mellitus.  The researchers 
determined preoperative hyperglycemia to be the main risk factor for development of an 
infection postoperatively.  Twenty (5%) out of the 400 diabetic patients developed 
postoperative infections which included: lung infections (0.5%), superficial sternal 
wound infections (0.75%), infection of the donor site (1%), mediastinitis (1.25%), and 
urinary tract infections (1.5%) (Guvener et al., 2002).  It was also concluded diabetics 
had a higher incidence of early mortality compared to nondiabetics (3% vs 1.73%, p = 
0.048) (Guvener et al., 2002).  
Likewise, a prospective study conducted by O’Sullivan et al. (2006) focused on 
the impact of hemoglobin A1c (HbA1c) levels on adverse outcomes in non-diabetic and 
diabetic patients undergoing elective and emergency vascular surgery.  For six months 
the researchers collected HbA1c levels on 165 patients.  Patients were classified into four 
groups determined by their plasma HbA1c levels: £ 6%, 6.1-7%, 7.1-8%, or > 8%.  
Outcomes were determined on any cause of 30-day or 6-month morbidity and mortality.  
Forty-three out of 165 (26.1%) patients had diabetes.  The term “suboptimal” was used to 
describe nondiabetic patients with HbA1c levels of > 6 to £ 7% and diabetic patients with 
HbA1c levels of > 7% (O’Sullivan et al., 2006).  The researchers concluded the 
suboptimal non-diabetic patients had significantly higher rates of general 30-day 
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morbidity versus patients with HbA1c levels of £ 6% (56.5% vs 15.7%, p < 0.001).  
Correspondingly, when compared to diabetic patients with HgbA1c levels of £ 7%, 
suboptimal diabetics with HbA1c levels of > 7% also had a higher rate of morbidity over 
30 days (59.1% vs 19%, p = 0.018) (O’Sullivan et al., 2006).  In conclusion, the 
investigators determined, with a multivariate analysis, a suboptimal HbA1c may infer 
prognostic significance in patients enduring vascular surgery (O’Sullivan et al., 2006).  
Due to the increased rate of morbidity related to hyperglycemia, perioperative blood 
sugar management becomes an essential part of anesthetic care.  The use of 
dexamethasone has shown deleterious effects on blood sugars (Joshi et al., 2010), 
therefore this study evaluates its use for PONV in the diabetic patient and the effects on 
blood sugar levels. 
Diabetic Autonomic Neuropathy and Gastroparesis.  According to gastric 
emptying studies done using radio isotopic techniques, approximately 50% of insulin 
dependent diabetic patients acquire autonomic neuropathy that results in impaired gastric 
emptying (Kadoi, 2010).  Neuropathy is caused by two mechanisms.  The first 
mechanism is related to vascular thickening which causes neural ischemia and 
dysfunction.  The second mechanism is due to Schwann cell demyelination leading to 
slow neural conductance.  Neuropathy can be of somatic nature, which usually occurs 
first.  The patient experiences the loss of proprioception, touch, and sensation (Grossman 
& Porth, 2014).  Autonomic neuropathy affects both the sympathetic and 
parasympathetic nervous systems.  Sympathetic denervation affects small arterioles; the 
nerves are either absent or located at a distance from the arteriole.  Vagal impairment can 
be manifested by a decrease in cardiac response and decreased parasympathetic tone.  
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This decline in vagal function leads to postural hypotension, sweating abnormalities, 
impotence, diarrhea or gastroparesis.  There is a 5-year mortality rate of greater than 50% 
when a patient develops gastroparesis or postural hypotension (Miller et al., 2015).  
Diabetic patients with autonomic neuropathy are at an elevated risk for PONV and gastric 
aspiration due to gastroparesis.  This is of clinical significance when diabetic patients 
present for surgery, specifically emergency procedures in which they have not been 
fasting (Miller et al., 2015).  A case report published by Tokumine et al. (2005) discussed 
a 28-year-old patient with a history of type I diabetes since age 12.  The patient presented 
for an elective eye procedure and had been fasting for 12 hours.  Upon induction of 
anesthesia the patient vomited and aspirated stomach contents that he had consumed 24 
hours prior to surgery (Tokumine et al., 2005).  The authors report that 30% of patients 
with type II diabetes and 58% of patients with type I diabetes have impaired gastric 
emptying.  Consideration of delayed gastric transport having the potential to increase the 
incidence of PONV, coupled with an increased risk of aspiration of gastric contents is 
imperative knowledge when developing an anesthetic plan for diabetic patients 
(Tokumine et al., 2005).  
Postoperative Nausea Vomiting  
Physiology.  Postoperative nausea and vomiting develop when an ill-defined area 
in the brain known as the “vomiting center” is stimulated by one or more of the five 
primary afferent neuronal pathways: the chemoreceptor trigger zone (CRTZ), the vagal 
afferents of the gastrointestinal tract, the vestibular system pathway, cerebral cortex 
afferent pathway, and afferents from the midbrain.  Stimulation of one or more of these 
pathways occurs via activation of muscarinic, histamine, dopamine, or serotonin 
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receptors (Shaikh et al., 2016).  The CRTZ lacks the blood brain barrier, allowing for 
interaction and detection of emetogenic substances by the central nervous system via the 
bloodstream.  Apomorphine and opioids act on this area via serotonin (5-
hydroxytryptamine [5-HT]), dopamine (D2), M3- muscarinic, and histamine (H1) 
receptors. (Miller et al., 2015).  The vagal mucosal afferent pathway contains 5-HT, M3, 
and H3 receptors.  This pathway is stimulated by nitrous oxide, opioids, cardiac 
glycosides, cytotoxic drugs, levodopa, bromocriptine, and ipecac (Shaikh et al., 2016). 
The vestibular pathway contains H1 and muscarinic receptors, which are receptive to 
nitrous oxide.  This area is also stimulated heavily by positional changes, ear surgery, and 
motion sickness. The cerebral cortex is fed and activated by emotions, fear, memory, 
smell, sight, and taste.  Nausea will result once the cerebral cortex has been stimulated in 
such a manner.  Lastly, the midbrain receives sensory information from the pharynx via 
the gag reflex, esophagus, stomach, and upper portions of the small intestines which is 
then conveyed to the vomiting center (Shaikh et al., 2016). 
The vomiting center is located in the reticular formation in the brainstem (Shaikh 
et al., 2016).  Once stimulated, efferent motor signals are transferred via cranial nerves V, 
VII, IX, X, and XII to the upper gastrointestinal (GI) tract.  The lower GI tract is then 
stimulated via cranial nerve X and sympathetic nerves.  Signals are subsequently relayed 
to the diaphragm and abdominal muscles via the spinal nerves initiating the act of 
vomiting (Hall, 2011).  
Risk Factors.  There are many risk factors that can contribute to the development 
of PONV.  Apfel et al. (2012) conducted a systematic review in which 22 studies with a 
total of 95,154 patients were included.  The studies were pooled together to evaluate 
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independent risk factors and other noncontributory factors.  The researchers searched 
PubMed, EMBASE, and Cochrane databases for any available evidence.  They did not 
restrict their search with any publication dates or language requirements.  They also hand 
searched the reference lists of the studies found.  Three individual investigators 
systematically evaluated the retrieved studies.  Observational studies with more than 500 
adults as well as randomized controlled trials were included.  Data extraction was done 
by one researcher and validated by a second individual investigator (Apfel et al., 2012).  
Statistical analysis was performed with the Review Manager and bias in publication was 
evaluated for all independent predictors with statistical significance. From the cohorts, 
odd ratios (OR) were calculated by allotted point estimates for anesthesia related, patient-
specific, and surgery related factors.  There were five independent factors related to 
anesthesia, eight patient specific factors, and 14 surgical risk factors identified (Apfel et 
al., 2012).  
Female gender was found to be the strongest patient-specific independent risk 
factor with an OR of 2.57 (Apfel et al., 2012).  The second strongest was having a history 
of PONV and/or motion sickness (OR 2.09); followed by being a non-smoker (OR 1.82).  
History of migraine was also found to be significant (OR 1.77).  ASA status, BMI, and 
age were not as significant (OR 1.21, 1.00, and 0.88 per decade, respectively) (Apfel et 
al., 2012). Of the anesthesia related risk factors, volatile agents were found to have the 
highest significance (OR 1.82).  Next was the duration of anesthesia, per hour, (OR 1.46).  
The use of nitrous oxide followed close behind (OR 1.45).  The fourth and fifth 
anesthesia related factors contributing to the development of PONV were the use of 
opioids: postoperatively (OR 1.39) and intraoperatively (OR 1.03) (Apfel et al., 2012). 
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The researchers identified 13 surgeries that contributed to PONV.  The surgery with the 
highest incidence of developing PONV was a cholecystectomy (1.90).  Laparoscopic and 
gynecologic procedures followed thereafter (OR 1.37 and 1.24, respectively).  The other 
surgeries that did not have clinical significance are: ENT, thyroid, ophthalmologic, 
orthopedic, abdominal, plastic, neurological, and head and neck surgery (Apfel et al., 
2012). 
Risk Assessment for PONV.  To better facilitate identification of risk factors, it 
is essential to assess individual patient’s risks for PONV.  The two most frequently used 
risk assessment tools for PONV are the Apfel score and the Koivuranta score (Gan et al., 
2014). 
The Apfel scoring system was developed after data from two independent studies 
were combined and cross analyzed (Apfel et al., 1999).  A simplified risk score was 
created and cross-validated with the original scores concluding the discriminating power 
was not altered with the simplification.  As a result, a final score was created consisting 
of the following four predictors: female gender, history of PONV, history of motion 
sickness, being a nonsmoker, and the use of opioids in the postoperative period (Apfel et 
al., 1999).  The presence of 0, 1, 2, 3, or 4 risk factors corresponds with the incidence of 
PONV as 10%, 20%, 40%, 60%, and 80% respectively.  Patients are scored as “low”, 
“medium”, or “high” based on the number of risk factors they have; 0 – 1, 2, or 3, 
respectfully (Gan et al., 2014). 
The Koivuranta score was developed from a prospective interview-based survey 
of 1107 inpatients.  Each patient received a 78-item questionnaire that accompanied them 
throughout their hospital stay.  Information was collected regarding patient 
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characteristics, presumed risk factors, details regarding the anesthetic and surgical 
procedure, and occurrence of nausea and vomiting.  The study determined the most 
significant factors associated with an increased incidence of nausea and vomiting were: 
female gender, history of PONV, extended duration of surgery, being a nonsmoker, and 
history of motion sickness.  Thus, the Koivuranta score was developed (Koivuranta et al., 
1997). 
In a study done by van den Bosch et al. (2005) to validate the Apfel and 
Koivuranta scoring systems, 1388 adult patients undergoing a variety of surgical 
procedures were screened.  The prognostic accuracy of each scoring system was 
evaluated based on prediction of developing one episode of nausea and/or vomiting 
within 24 hours postoperatively.  This study determined that both scoring systems, based 
on calibration and discrimination, were less accurate than anticipated compared to 
previous studies.  According to van den Bosch et al. (2005), both risk assessments 
provided too extreme of prediction. Apfel’s area under the Receiver Operating 
Characteristic curve (ROC area) was 0.63 and Koivuranta’s ROC area was determined to 
be 0.66.  The ROC area can range from discrimination equal to that of chance (0.5) to 
perfect discrimination (1.0).  These numbers are considerable, especially related to over 
treatment, which can expose patients to unnecessary side-effects.  This can be detrimental 
in diabetic patients treated with dexamethasone if hyperglycemia ensues: poor wound 
healing, dehydration, hyperosmolar states and increased risk of infection (Joshi et al., 
2010). 
Management of PONV.  The management of PONV requires an individualized 
approach to each patient in which medical history, risk factors, cost-effectiveness must be 
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considered.  In 2014, SAMBA published consensus guidelines for the management of 
PONV, highlighting the importance of combination therapy for PONV prophylaxis.  It is 
noted in the statement that combination regimens with optimal dosing have yet to be 
established, however, the statement did include two algorithms based on individualized 
risk factors (Gan et al., 2014).  Each algorithm has suggestions for prophylactic 
interventions and treatment of PONV.  A risk assessment is conducted first for each 
patient using either Koivuranta or Apfel scoring tool.  Next, depending on provider 
preference of implementing prophylactic measures, interventions are made based on 
patients identified risk category.  The first table (Table 1) does not provide an 
intervention for patients identified as “low-risk”.  For “medium-risk” patients, a two-drug 
combination is recommended for prophylaxis; and a three-drug combination for “high-
risk” patients.  The second table (Table 2) provides prophylactic intervention for all 
patients regardless of risk.  Gan et al. (2014) does stress the drugs suggested for use in 
each table are examples of interventions that could be used, however each patient’s 
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Table 1 
Risk-Adapted PONV-Prevention Algorithm (With No Prevention in Low-Risk Patients) 
Estimated risk for PONV, as determined by a risk score 




(“wait and see”) 
Drug A + Drug B or 
TIVA 
Drug A + Drug B + 
TIVA 
 





1. Drug B 
2. Drug C (in case 
of ineffectiveness 
of treatment in 
stage 1) 
1. Drug C 
2. Drug D (in case of 
ineffectiveness of 
treatment in stage 1) 
1. Drug C 
2. Drug D (in case of 
ineffectiveness of 
treatment in stage 1) 
Note. Example interventions for adult patients: Drug A = dexamethasone 4mg; Drug B = 
ondansetron 4mg; Drug C = droperidol 1mg; Drug D = dimenhydrinate 1mg/kg. TIVA = 
total intravenous anesthesia i.e. propofol induction and maintenance, without use of 
nitrous oxide (Gan et al., 2014).  
 
Table 2 
PONV-Prevention Algorithm in All Patients Including Low-Risk Patients Plus Additional 
Interventions for High-Risk Patients 
Estimated risk for PONV, as determined by a risk score 
 Low Medium High 
Interventions 
for prophylaxis 
Drug A + (Drug B 
or TIVA) 
Drug A + (Drug B or 
TIVA) 
Drug A + Drug B + 
TIVA 





1. Drug C2. Drug D 
(in case of 
ineffectiveness of 
treatment in stage 
1) 
1. Drug C 
2. Drug D (in case of 
ineffectiveness of 
treatment in stage 1) 
1. Drug C 
2. Drug D (in case of 
ineffectiveness of 
treatment in stage 1) 
Note. Example interventions for adult patients: Drug A = dexamethasone 4mg; Drug B = 
ondansetron 4mg; Drug C = droperidol 1mg; Drug D = dimenhydrinate 1mg/kg. TIVA = 
total intravenous anesthesia i.e. propofol induction and maintenance, without use of 
nitrous oxide (Gan et al., 2014). 
 
A randomized, controlled trial was completed in 2004 by Apfel et al., in which 
5,199 patients were enrolled for evaluation of treatment for postoperative nausea and 
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vomiting.  The trial was of factorial design in which as many as three antiemetic 
interactions were evaluated.  Of the patients enrolled, 4,123 subjects were randomly 
allocated to 1 of 64 prophylactic interventions: no ondansetron or 4mg of ondansetron; no 
dexamethasone or 4mg of dexamethasone; no droperidol or 1.25mg of droperidol; 
volatile anesthetic or propofol; nitrous oxide or nitrogen; fentanyl or remifentanil.  The 
other patients were randomly assigned to one of the four first interventions (Apfel et al., 
2004).  Nausea and vomiting 24 hours postoperatively were the primary outcome, 
measured blindly.  The study concluded dexamethasone, droperidol, and ondansetron 
independently reduced the risk of PONV by approximately 26%.  A 19% reduction in 
risk was observed with the use of propofol and a 12% reduction with the use of nitrogen.  
The combination of nitrogen and propofol (TIVA) were similar to the other antiemetics, 
when used independently.  The authors concluded that due to the variety of mechanisms 
of actions of each antiemetic and similar effectiveness, the first choice should be based 
on patient profile or the most cost-effective intervention.  They also reported low risk 
patients rarely need prophylaxis, a single intervention may be beneficial in patients with 
moderate risk and high-risk patients should have multiple interventions (Apfel et al., 
2004). 
In a meta-analysis done by Henzi et al. (2000) the use of dexamethasone for the 
prevention of PONV was conducted using data from 17 trials with 1,946 patients 
(children and adults).  Analysis of the data revealed: 598 patients received 
dexamethasone, 582 patients received either ondansetron, granisetron, droperiodol, 
metoclopramide or perphenazine, 423 patients received a placebo; and 343 received a 
combination of dexamethasone with either ondansetron or granisetron.  With placebo, the 
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incidence of early PONV (0 to 6 hours postoperatively) was 35%, and late PONV (0 to 
24 hours postoperatively) was 50%.  In order to prevent early and late vomiting in adult 
patients, the researchers found 7.1 (95% CI 4.5 to 18) and 4.3 (2.3 to 2.6) was the number 
needed to treat, respectively (Henzi et al., 2000).  In examining the combination of 
dexamethasone with a 5-HT3 receptor antagonist: ondansetron or granisetron, the number 
needed to treat was 7.7 (4.8 to 19) compared to the 5-HT3 receptor antagonist alone at 7.8 
(4.1 to 66).  The data from the other antiemetic options were deemed incomparable and 
therefore inconclusive.  The researchers concluded the most optimal prophylactic 
treatment regimen to prevent PONV in healthy patients was with a combination of 
dexamethasone and a 5-HT3 receptor antagonist (Henzi et al., 2000). 
The prophylactic management of PONV in diabetic surgical patients can be 
complicated especially when the use of dexamethasone is widely popular.  SAMBA’s 
consensus statement regarding the management of diabetic patients undergoing 
ambulatory surgery published in 2010 approves of the use of dexamethasone 4mg for 
prophylactic treatment of PONV (Joshi et al., 2010).  However, in 2014, SAMBA’s 
consensus statement on the management of PONV undergoing ambulatory surgery 
reports conflicting evidence regarding dexamethasone dosing and implications on BG 
levels.  This consensus statement reports dexamethasone use is relatively contraindicated 
in labile diabetic patients (Gan et al., 2014).  This current systematic review examines the 
data regarding these statements and further evaluates the effects of dosing, 4mg or 8mg, 
of dexamethasone on blood sugars postoperatively.  
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Pharmacologic Antiemetic Classifications 
Dopamine Antagonists.  The two main dopamine antagonists are 
metoclopramide and droperidol; however, haloperidol and perphenazine also used.  
Metoclopramide promotes gastric motility, increases gastroesophageal sphincter tone, 
and relaxes the pylorus and duodenum. It is also an antidopaminergic, with its ability to 
cross the BBB and act on the CRTZ.  However, due to its extrapyramidal side effects, it 
is not used as frequently.  Droperidol is a well-established antiemetic exerting its effects 
on the GABA receptors in the CRTZ zone.  This drug, however, has become 
controversial since acquiring a black box warning for association of patients developing 
torsades de pointes or severe arrhythmias due to QT prolongation (Miller et al., 2015). 
Haloperidol is another dopamine agonist that is used as an antiemetic.  
Haloperidol acts on the CRTZ and has been used commonly for nausea and sickness 
caused by chemotherapy.  It also has peripheral GI effects by relaxing the gastric 
sphincter (Miller et al., 2015). Perphenazine is also a dopamine antagonist that is known 
for its highly potent neuroleptic effect (Miller et al., 2015). 
Histamine Antagonists.  Two common antihistamines are meclizine and 
promethazine.  Both of these drugs antagonize histamine receptors.  They also exert 
effects on the vestibular apparatus by blocking acetylcholine receptors.  Another 
uncommon antihistamine used is, dimenhydrinate.  This drug acts on the H1 receptor and 
also has weak antimuscarinic activity.  It has been used for the treatment of motion 
sickness (Miller et al., 2015).  
Anticholinergic Antagonists. Transdermal scopolamine exerts its effects on the 
vestibular nuclei by inhibiting cholinergic transmission.  It also works on the 
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parasympathetic nervous system by way of competitive inhibition of muscarinic 
receptors.  It is used primarily for patients with a history of motion sickness. 
Serotonin Antagonists. Agents such as ondansetron, dolasetron, palonosetron, 
and granisetron are 5-HT antagonists that act centrally and also block vagal afferents 
located in the gut.   
Neurokinin- 1 Receptor (NK-1) Antagonists. Aprepitant, Cospitant, and 
Rolapitant are part of a new group of antiemetics.  Their mechanism of action is blocking 
NK-1 receptors located in the NTS and areas in the reticular formation (Shaikh et al., 
2016). 
Propofol. Propofol is a hypnotic-sedative that is frequently used for the induction 
and maintenance of general anesthesia.  It is also used in conjunction with regional 
anesthesia, local anesthesia, and for monitored anesthesia care.  It exerts its effects by 
increasing chloride conductance at the GABAa receptor.  Propofol has been found to have 
anti-emetic properties and its use is recommended for reducing the baseline risk of 
developing PONV. Sub-hypnotic doses of propofol have also been studied independently 
for antiemetic properties (Gan et al., 1997).  
Dexamethasone. The corticosteroid dexamethasone provides an antiemetic effect 
by inhibiting the NTS in addition to inhibiting the synthesis of prostaglandins.  The 
blocking of prostaglandin synthesis results in better emesis control due to its effect on the 
sensitization of emesis controlling neurotransmitters (Shaikh et al., 2016).  In a study 
performed by Wang et al. (2000) the minimum effective dose of dexamethasone was 
examined in women undergoing a thyroidectomy.  Two hundred seventeen women were 
enrolled in a randomized, double-blinded, placebo-controlled study in which 
 22  
dexamethasone was administered at 10mg, 5mg, 2.5mg, 1.25mg, or saline.  The results 
concluded that the minimum effective dose of dexamethasone for preventing PONV is 
5mg and there were no significant differences between the groups receiving 10mg doses 
compared to 5mg doses.  This finding can be clinically significant in mitigating the side 
effects associated with the use of dexamethasone.   
Additional uses for dexamethasone. The use of corticosteroids, specifically 
dexamethasone, has been shown not only to be efficacious as an antiemetic, it has also 
been shown to be successful in treating post-operative pain.  A randomized, double-blind, 
placebo-controlled study performed by Kardash et al. (2008) aimed to analyze the effects 
of single-dose dexamethasone prior to total hip arthroplasty on dynamic pain.  Prior to 
surgery, fifty patients receiving propofol sedation with spinal anesthesia were placed into 
two groups: group 1received 40mg of dexamethasone and group 2 received IV saline.  
Postoperative pain was measured with the 0-10 numeric rating scale (NRS) every 4 hours 
for 48 hours.  The results elicited a reduction is dynamic pain in group 1 (NRS score: 2.7, 
95% CI: 2.2-3.1 vs 6.8, 6.4-7.2; p< 0.0001).  They also noted there was no morphine 
consumption or significant pain at rest at any given time.  Of note, seven patients from 
the control group were treated for nausea compared to only one from group 1 (Kardash et 
al., 2008).  The researchers also measured an anti-inflammatory marker, C-reactive 
protein, in a subgroup of 25 patients 48 hours postoperatively.  They concluded patients 
who received dexamethasone had markedly reduced levels of C-reactive protein (52.4 
mg/mL, 28.2-76.6 vs 194.2, 168.9-219.4; p < 0.0001) (Kardash et al., 2008). 
As the above study notes, dexamethasone has been used as an anti-inflammatory.  
Usage of dexamethasone has been shown to decrease prostaglandin production by 
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inhibiting cyclooxygenase type II, phospholipase and other major cytokines including C-
reactive protein, tumor necrosis factor (TNF), and several interleukins (IL) (Nagelhout & 
Plaus, 2014).  In a study done by el Azab et al. (2002) nine out of seventeen patients 
(group 1) undergoing cardiopulmonary bypass received dexamethasone 100mg before 
anesthesia induction.  The eight other patients were placed in the control group (group 2).  
Perioperative plasma levels were measured for TNF, IL-4, IL-6, IL-8, and IL-10.  
Postoperatively it was concluded that IL-8 and TNF did not significantly increase in 
group 1 as compared to group 2 which had a greater increase than the preoperative values 
(p < 0.05).  Both groups had an increase in IL-6; However, group 1 had less of an 
increase compared to group 2 (p < 0.05).  Group 1 had a higher increase of IL-10 
compared to group 2 (p < 0.05).  Finally, group 2 had a decrease in IL-4, however it did 
not change in group 1 (p < 0.05) (el Azab et al., 2002).  Of note postoperatively, group 2 
did have hyperthermia, tachycardia, increased pulmonary artery pressure, increased 
respiratory rate, and a more prolonged stay in the intensive care unit.  Despite the low 
number of participants, the authors concluded from their study that postoperative 
outcomes may improve from dexamethasone use prior to cardiac surgery due to the anti-
inflammatory effect on circulating cytokines (el Azab et al., 2002). 
Steward et al. (2011) account that there have not been any adverse effects from a 
single dose of dexamethasone.  However, Nalgelhout & Plaus (2014), claim a transient 
increase in blood glucose levels can be appreciated after the administration of 
dexamethasone.  However, a momentary increase in BG level for a diabetic may 
negatively impact health outcomes.  Patients with hyperglycemia during the surgical 
period are at a greater risk for electrolyte imbalances, dehydration, increased risk of 
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infection, fluid shifts, compromised wound healing, and ketoacidosis (Joshi et al., 2010).  
Despite it’s proven anti-inflammatory effects and anti-pain properties, the use of 
dexamethasone in the diabetic population has been controversial related to the degree of 
BG fluctuation.  This systematic review examines more recent studies to determine the 
extent in which dexamethasone effects BS in the diabetic patient.  
Next, the theoretical framework will be presented. 
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Theoretical Framework 
A guide for evaluating systematic reviews was identified by Moher et al. in 2009. 
They articulated that a systematic review incorporates “a clearly formulated question that 
uses systematic and explicit methods to identify, select, and critically appraise relevant 
research, and to collect and analyze data from the studies that are included in the review” 
(Moher et al., 2009, p. 264).  This process is of utmost importance for health care 
workers due to many policies, practices, and further research are guided by systematic 
reviews.  In order to guide this systematic review, the Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses (PRISMA) theoretical framework will be used.  
 The PRISMA theoretical framework has a 27-point checklist to guide the 
researcher through critical appraisal of each RCT to be used.  This ensures an analytical 
and unbiased evaluation is made of each RCT.  The checklist provides the researcher 
with a step-by-step guide for examining the RCT, including their introduction, methods, 
results, and discussion.  Once the initial research has been conducted, PRISMA uses a 
flow diagram to elicit the extent of the search.  The four phases consist of identification, 
screening, eligibility, and studies included. This allows the researcher to present the 
extent of their search and screening process for their systematic review (Moher et al., 
2009). 
In order to facilitate an unbiased, thoroughly conducted systematic review, the use 
of PRISMA will be implemented when examining the use of dexamethasone in adult 
diabetic surgical patients to prevent PONV and the impact on blood glucose levels. 
Next, the methods will be presented. 
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Methods 
Purpose 
The purpose of this study was to examine the use of dexamethasone and the 
impact on blood glucose levels for the prevention of PONV in adult diabetic surgical 
patients.  In order to thoroughly examine this issue, a systematic review of multiple 
randomized control trials was completed.   
Inclusion/Exclusion Criteria 
Inclusion criteria for the studies included: (a) adults 18 years of age and older, (b) 
patients undergoing surgery, (c) the use of dexamethasone for PONV, (d) patients with 
the diagnosis of diabetes mellitus type I or type II. Exclusion criteria for the studies 
included: (a) pediatric patients, (b) gestational diabetic patients. 
Search Strategy 
A detailed search was performed using CINAHL (Cumulative Index to Nursing 
and Allied Health Literature) and MEDLINE.  Keywords utilized were: “dexamethasone” 
AND “diabet*” AND “postoperative nausea and vomiting” OR “PONV”.  Restrictions of 
English language and human subjects were implemented to the search.  
Data Collection 
Data collected from each study included: study purpose, design, and location; 
number of subjects included, type of surgery; baseline, intraoperative, and postoperative 
blood glucose levels; along with dexamethasone dosage and the use of placebo and/or 
other anti-emetic pharmacologic treatment. 
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Critical Appraisal 
Literature collected was critically appraised using Critical Appraisal Skills 
Progamme (CASP).  CASP (Table 3) combines a three-step approach and a checklist to 
guide the researcher in ensuring validity when synthesizing research (Critical Appraisal 
Skills Programme, 2017).  After completion of each study evaluation and summary a 
comprehensive cross study analysis was completed. 
Table 3 
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist. 
 
A. Are the results of the trial valid? Yes Can’t tell No 
1. Did the trial address a clearly focused 
issue? 
   
2. Was the assignment of patients to 
treatments randomized? 
   
3. Were all of the patients who entered 
the trial properly accounted for at its 
conclusion? 
   
4. Were patients, health workers, and 
study personnel “blind” to treatment? 
   
5. Were the groups similar at the start of 
the trial? 
   
6. Aside from the experimental 
intervention, were the groups treated 
equally? 
   
B. What are the results? Yes Can’t tell No 
7. How large was the treatment effect?    
8. How precise was the estimate of the 
treatment effect? 
   
C. Will the results help locally? Yes Can’t tell No 
9. Can the results be applied in your 
context? 
   
10. Were all clinically important 
outcomes considered? 
   
11. Are the benefits worth the harms and 
costs? 
   
Note:  CASP checklist completed on all studies that met inclusion criteria. 
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Data Synthesis & Cross Study Analysis 
Upon completion of each individual study evaluation and summary a 
comprehensive cross study analysis was completed.  The cross-study analysis compared 
dexamethasone dosing, use of placebo or other anti-emetic pharmacologic treatment, and 
the evaluation of baseline, intraoperative, and postoperative blood glucose levels. 
Next, the results will be presented.   
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Results 
Figure 1  
Completed PRISMA flow diagram demonstrating article identification, screening, 
eligibility, and inclusion (Moher et al., 2009). 
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The completed PRISMA flow diagram as depicted in Figure 1 illustrates a visual 
analysis of how the four final studies were gathered to complete this systematic review.  
An initial search of the selected databases, CINAHL and MEDLINE, was completed 
using the search term “dexamethasone”, resulting in 72,395 studies.  The addition of 
search term “diabet*” narrowed the results to 2,520 studies.  By adding “postoperative 
nausea and vomiting” OR “PONV” to the search field, the results were narrowed down to 
35 studies.  A total of seven articles were excluded due to duplication.  After article 
screening, 31 studies were excluded due to failing to meet previously identified inclusion 
criteria.  Lastly, the remaining four studies were appraised and chosen to complete this 
systematic review to examine the use of dexamethasone and the impact on blood glucose 
levels for the prevention of PONV in adult diabetic surgical patients. 
Each of the four studies selected and appraised for this systematic review include 
a description of the results with applicable study findings identified.  Appendix A (Tables 
A1 – A4) depicts study specific data that was collected for each individual study.  Each 
individual table includes the following key information: purpose of the study, study 
design, location, sample make up, methods used, and surgical procedure performed.  
Following is Appendix B (Tables B1 – B4) which lists the outcome data that was 
collected.  Study specific findings include: BG sample times, baseline BG reading, mean 
peak BG levels and maximum BG levels.  Each table does have a degree of 
individualization due to variance in each study.  Next, Appendix C (Tables C1 – C4) lists 
the critical appraisal data tables of individual studies that were created to assess the 
legitimacy, consistency, and applicability through a three-part, 11 question series.  
 31  
Finally, Appendix D, a cross-study analysis data table was created to assist in comparing 
the results of each individual study.  
Individual Studies 
The single-center, prospective, double-blind randomized trial by Nazar et al. 
(2009) (Appendix A – 1) investigated the effect of administering dexamethasone in the 
perioperative period on patients with poor glycemic control undergoing laparoscopic 
Roux-en-Y gastric bypass surgery.  A total of 30 obese patients (BMI >35kg/m2) with 
impaired glucose tolerance were randomly divided into two groups.  Group 1, the 
dexamethasone group consisted of 15 participants while the remainder 15 participants 
compromised group 2, the control group.  Group 1 received dexamethasone 8mg IV 
immediately after induction of anesthesia, while Group 2 received 2ml of isotonic saline 
IV at the same designated time.  Standardized surgical technique, per institution protocol, 
was followed and the participants received a total gastroplasty with gastric pouch (30ml) 
with 150 cm exclusion of small intestine and gastrojejunal anastomosis.  Baseline BG 
level was obtained preoperatively with IV placement. BG levels were reassessed every 
two hours after surgical start for 12 hours. A difference of 45 mg/dl in peak glucose 
values between groups was considered statistically significant. The BG levels were not 
corrected during the study. 
Outcomes of this study by Nazar et al. (2009) (Appendix B – 1) concluded that all 
BG samples measured after the beginning of surgery were higher compared to baseline in 
both groups.  Group 1, the dexamethasone group, exhibited higher BG levels from the 6th 
to the 12th hour after anesthesia compared to the control group.  Group 2 maximum BG 
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levels were found to be significantly different compared to Group 1 (Group 1: M = 187.2 
versus Group 2: M = 158.4) (p-value <0.05) (Nazar et al., 2009). 
 When assessing the integrity of the study using the CASP questionnaire 
(Appendix C, Table C – 1), the trial addressed a clearly focused issue in which all of the 
participants were randomized to treatment and it was also noted that study personnel, 
participants, healthcare workers were “blind” to treatment.  Both groups were similar at 
the start of the trial, treated equally aside from the experimental intervention, and all of 
the participants were accounted for at the end of the trial.  The results can be applied to 
diabetics undergoing surgical procedures however the study is limited due to the small 
number of participants (Nazar et al., 2009).  Due to a hyperglycemia having an impact on 
wound healing and infection rates, this study did not examine all clinically important 
outcomes (Guvener et al., 2002).  As a result, it is inconclusive whether the benefits 
outweigh the risks. 
This single -center, placebo-controlled study by Abdelmalak et al. (2013) was 
randomized to dexamethasone or placebo and stratified by the presence or absence of 
diabetes (Appendix A, Table A-2).  The patients were part of a larger underlying study in 
which they were randomized to either tight glucose control with a target plasma 
concentration of 80 to 110 mg/dl or conventional glucose control of 180 to 200 mg/dl, 
regardless of diabetic status: The Dexamethasone, Light Anesthesia and Tight Glucose 
Control [DeLiT] Trial (Abdelmalak et al., 2013).  This study’s purpose was to investigate 
the change of blood glucose, from preoperative to maximal intraoperative, after 
administration of dexamethasone 8mg IV to diabetic and nondiabetic patients undergoing 
noncardiac surgery under general anesthesia.  A total of 185 patients ≥ 40 years of age, 
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restricted to the conventional glucose group, were divided into four groups.  Group 1 
consisted of 21 diabetic patients who received dexamethasone 8mg IV 1-2 hours prior to 
incision, Group 2 comprised of 28 diabetic patients who received a placebo, Group 3 
consisted of 69 nondiabetic patients who received dexamethasone 8mg IV 1-2 hours prior 
to incision, and Group 4 comprised 67 nondiabetic patients who received a placebo.  
Fasting BG levels were obtained preoperatively. A mean group difference of ≥ 28 mg/dl 
signified clinical relevance.  Insulin was given when BG levels were >215 mg/dl to 
maintain target range of 180 to 200 mg/dl.  Baseline BG was assessed preoperatively and 
then reassessed at least hourly when stable and every 30 minutes after intervention.  
Stable BG was defined by Abdelmalak et al. (2013) as a BG < 215 which required no 
intervention such as insulin bolus or adjustment of insulin infusion, with two 
consecutively similar BG readings.  Interventions included insulin boluses or adjustment 
of insulin infusion rate.  All patients received a general anesthetic with sevoflurane in air 
and oxygen for a noncardiac surgery in addition to a standardized infusion of IV fentanyl 
(Abdelmalak et al., 2013). 
Outcomes of this study by Abdelmalak et al. (2013) (Appendix B, Tables B – 2.1-
2) demonstrated the mean maximal BG change did not change significantly between the 
diabetic and nondiabetic patients (p=0.39).  Dexamethasone increased the mean maximal 
BG change compared to control in nondiabetic patients (Group ND1: M = 86mg/dl, 
versus Group ND2: M = 58mg/dl) (p=0.0012).  However, there wasn’t a hyperglycemic 
response to dexamethasone observed in diabetic patients (Group DM1: M = 63mg/dl 
versus Group DM2: M = 63mg/dl), (p=0.99) (Abdelmalak et al., 2013). 
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When assessing the integrity of the study using the CASP questionnaire 
(Appendix C, Table C – 2), the trial addressed a clearly focused issue in which all of the 
participants were randomized to treatment and it was also noted that study personnel, 
participants, healthcare workers were “blind” to treatment.  The groups were not similar 
at the start of the trial, diabetic patients were outnumbered 49 compared to 136.  Also, 
interventions were implemented aside from the experimental intervention for patients 
with BG >215mg/dl.  All of the participants were accounted for at the end of the trial.  
The results can be applied to patients undergoing surgical procedures however the study 
is limited due to treatment received when BG >215mg/dl (Abdelmalak et al., 2013).  Due 
to a hyperglycemia having an impact on wound healing and infection rates, this study did 
not examine all clinically important outcomes (Guvener et al., 2002).  As a result, it is 
inconclusive whether the benefits outweigh the risks. 
The single-center, prospective, randomized trial by Tien et al. (2016) (Appendix 
A, Table A – 3) investigated the effect of prophylactic administration of dexamethasone 
or ondansetron for prevention of postoperative nausea and vomiting and the effects on 
blood glucose levels in non-diabetic and type-2 diabetic surgical patients.  A total of 85 
adult English-speaking patients scheduled for a general anesthetic elective surgery 
anticipated to last >1 hour and expected to be admitted to the hospital for at least 24 
hours were divided into 4 groups.  Group 1 consisted of 20 non-diabetic participants who 
received dexamethasone 8mg IV at induction of anesthesia, Group 2 comprised 21 non-
diabetic participants who received 4mg ondansetron IV towards the end of the procedure, 
Group 3 consisted of 20 type 2 diabetic patients who received dexamethasone 8mg IV at 
induction of anesthesia, and Group 4 comprised 24 type 2 diabetic patients who received 
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ondansetron 4mg IV towards the end of the procedure.  Baseline BG was obtained 
preoperatively and sent to the central laboratory for measurement. A mean increase in BG 
levels by 30.6 mg/dl was to be considered significant. Additional BG samples were sent 
at set time intervals: 2 hours, 4 hours, and 24 hours.  A variety of surgical procedures 
were preformed and classified into the following groups: open gynaecological, 
laparoscopic gynaecological, open abdominal, laparoscopic abdominal, or other (Tien et 
al., 2016). 
Outcomes of this study by Tien et al. (2016) (Appendix B, Table B – 3) 
demonstrated in non-diabetic patients, the maximum BG was higher in those who 
received dexamethasone compared to those who received ondansetron (p = 0.04); the 
same conclusion was exhibited with type 2 diabetic patients who received dexamethasone 
compared to those who received ondansetron (p < 0.01). 
When assessing the integrity of the study using the CASP questionnaire 
(Appendix C, Table C – 3), the trial addressed a clearly focused issue in which all of the 
participants were randomized to treatment and it was also noted that study personnel, 
participants, healthcare workers were “blind” to treatment.  The groups were not similar 
at the start of the trial, patients selected for the study were diabetic and non-diabetic, of 
varying age, and received various types of surgery.  Also, an intervention of 
subcutaneous insulin was implemented aside from the experimental intervention for 
diabetic patients whose BG levels > 200 mg/dl.  All of the participants were not 
accounted for at the end of the trial, three out of 88 patients were discharged early from 
the hospital and considered lost to follow-up.  The results can be applied to patients 
undergoing surgical procedures however the study is limited due to treatment received 
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when BG >200mg/dl (Tien et al., 2016).  Due to a hyperglycemia having an impact on 
wound healing and infection rates, this study did not examine all clinically important 
outcomes (Guvener et al., 2002).  As a result, it is inconclusive whether the benefits 
outweigh the risks. 
The final study included in this systematic review is a single-center, prospective, 
placebo-controlled randomized trial by Purushothaman et al. (2018) (Appendix A, Table 
A – 4) investigated the effect of administering two low doses (4mg or 8mg) of 
dexamethasone on BG levels of diabetic and nondiabetic patients receiving spinal 
anesthesia for elective surgeries.  A total of 180 elective surgical patients aged 18 – 70 
years undergoing spinal anesthesia were divided into six groups: group 1, the diabetic 
control group consisted of 30 patients; group 2, consisted of 30 diabetics who received 
dexamethasone 4mg IV immediately prior to delivery of spinal anesthetic; group 3, 
consisted of 30 diabetics who received dexamethasone 8mg IV immediately prior to 
delivery of spinal anesthetic; group 4, the nondiabetic control group consisted of 30 
patients; group 5, consisted of 30 nondiabetics who received dexamethasone 4mg IV 
immediately prior to delivery of spinal anesthetic; and group 6, consisted of 30 
nondiabetics who received dexamethasone 8mg IV immediately prior to delivery of 
spinal anesthetic.  Baseline capillary BG level was obtained immediately prior to 
administration of dexamethasone or control and reassessed every hour for 7 hours. A 
mean BG change of 23 mg/dl was to be considered clinically significant. The test drugs 
were reconstituted to a volume of 5mls and given immediately prior to delivery of spinal 
anesthetic.  A standardized spinal anesthetic was followed using aseptic technique – a 25-
gauge Quincke needle was used to deliver 0.5% hyperbaric bupivacaine 15mg and 
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buprenorphine 60 mcg at either L2-L3 or L3-L4 midline approach.  A total of 133 general 
surgeries, 24 gynecologic, and 43 orthopedic/plastic and other surgeries were included 
(Purushothaman et al., 2018). 
Outcomes of this study by Purushothaman et al. (2018) (Appendix B, Table B – 
4.1-2) demonstrated that there was a rise in BG levels in both diabetic and nondiabetic 
groups who received dexamethasone. However, this rise was not clinically significant 
with a range of 10-15 mg/dl from baseline.  Blood glucose levels peaked at 240 minutes 
in group 2, the diabetic group that received 4mg dexamethasone IV, which was a 
statistically significant increase from baseline. Blood glucose levels in the group 3, the 
diabetic group that received 8mg dexamethasone IV peaked at 300 minutes.  Blood 
glucose levels peaked in the group 5, the nondiabetic group that received dexamethasone 
4mg IV, and group 6, the nondiabetic group that received dexamethasone 8mg IV, at 300 
minutes and 360 minutes, respectively. At 480 minutes, in comparison with the group 3, 
group 6 had a statistically significant increase in BG levels (Purushothaman et al., 2018). 
When assessing the integrity of the study using the CASP questionnaire 
(Appendix C, Table C – 4), the trial addressed a clearly focused issue in which all of the 
participants were randomized to treatment and it was also noted that study personnel, 
participants, healthcare workers were “blind” to treatment.  The groups were not similar 
at the start of the trial due to a variety of surgical procedures being performed.  However, 
the groups were treated equally aside from the experimental intervention, and all of the 
participants were accounted for at the end of the trial.  The results can be applied to 
diabetics undergoing surgical procedures however the study is limited due to the 
participants received a spinal anesthetic which is different compared to all of the other 
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studies who received a general anesthetic (Purushothaman et al., 2018).  Due to a 
hyperglycemia having an impact on wound healing and infection rates, this study did not 
examine all clinically important outcomes (Guvener et al., 2002).  As a result, it is 
inconclusive whether the benefits outweigh the risks. 
Cross-Study Analysis 
The cross-study analysis table (Appendix D) exhibits the PONV prophylaxis used 
for each study, as well as the major outcomes investigated including: Mean BG at 2 
hours, 4 hours, 6 hours, and 8 hours; as well as mean peak BG levels.  Each study had a 
varying time frame in which BG samples were measured.  Nazar et al. (2009) measured 
mean BG at all of the above time frames mentioned. Abdelmalak et al. (2013) did not list 
any BG levels for their four groups, instead listed overall mean peak BG levels.  Tien et 
al. (2016) listed mean BG for 2 hours, 4 hours and mean peak BG.  Purushothaman et al. 
(2018) listed all of the mean BG at all of the above time frames mentioned.   
All studies included dosing of dexamethasone 8mg IV in diabetic patients and 
was compared against a diabetic control (study 1, 2, and 4), a nondiabetic control (study 2 
and 4), nondiabetic patients receiving dexamethasone 8mg IV (study 2 and 4), 
nondiabetic and diabetic patients receiving ondansetron 4mg IV (study 3) and 
nondiabetic and diabetic patients receiving dexamethasone 4mg IV (study 4).  There was 
an increase in mean peak BG in diabetic patients receiving dexamethasone 8mg IV 
compared to diabetic control in study 1 and 4, however it was only clinically significant 
in study 1 (p<0.05).  In study 2 there was not a change in mean peak BG in the diabetic 
patients receiving dexamethasone 8mg IV compared to the diabetic control group (Group 
DM1: M = 209mg/dl versus Group DM2: M = 209mg/dl).  There was an increase in 
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mean peak BG in diabetic patients receiving dexamethasone 8mg IV compared to the 
nondiabetic control group in study 2 (Group DM1: M = 209mg/dl versus Group ND2: M 
= 154mg/dl) and study 4 (Group DM3: M = 168mg/dl versus Group ND4: M = 
105mg/dl).  In the diabetic groups receiving dexamethasone 8mg IV, there was a small 
increase in BG compared to nondiabetic patients receiving dexamethasone 8mg IV in 
study 2 (Group DM1: M = 209mg/dl versus Group ND1: M = 182mg/dl) and study 4 
(Group DM3: M = 168mg/dl versus Group ND6: M = 140mg/dl).  In study 3, the diabetic 
group receiving dexamethasone 8mg IV had an overall increase in mean peak BG 
compared to the diabetic group receiving ondansetron (Group DM3: M = 252mg/dl 
versus DM4: M = 192.6 mg/dl).  There was also an increase in BG in the diabetic group 
receiving dexamethasone 8mg IV compared to both nondiabetic groups receiving either 
dexamethasone or ondansetron, respectively (Group DM3: M = 252mg/dl versus Group 
ND1: M = 163.8mg/dl versus Group ND2: M = 140.4mg/dl).  In study 4, the diabetic 
group receiving dexamethasone 8mg IV had an increase in mean peak BG compared to 
the nondiabetic group that received dexamethasone 4mg IV (Group DM3: M = 168mg/dl 
versus Group ND5: M = 133mg/dl).  However, when the diabetic group receiving 
dexamethasone 8mg IV is compared to the diabetic group receiving dexamethasone 4mg 
IV, the latter group has a higher BG (Group DM3: M = 168mg/dl versus Group DM2: M 
= 169mg/dl).  
 Next, the summary and conclusions will be presented. 
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Summary and Conclusions 
In the United States, DM is the sixth most common cause of death, with severe 
implications on other leading causes of mortality: cardiovascular and cerebrovascular 
disease (Coursin et al., 2004).  The incidence of type 2 DM far outweighs type 1 with 8-
10% of all Americans or 95% of all diabetics having type 2.  This number is projected to 
double in the United States within the next several decades, affecting a third to a quarter 
of the population (Coursin et al., 2004).  This has significant implications for the health 
care system when there is an 18 – 22 year loss of estimated quality adjusted life years for 
patients with a diagnosis of diabetes.  Along with a loss of years lived, diabetics undergo 
an increased amount of surgeries and procedures, necessitate more hospitalizations, 
longer lengths of stay, and at greater cost compared to nondiabetic patients (Coursin et 
al., 2004).  As an independent risk factor for poor outcomes, hyperglycemia in the 
perioperative period becomes a major concern for the anesthetist.  Many type 2 diabetics 
fail to be diagnosed until the time of their procedure or illness, with as many as 50% of 
patients developing significant end organ compromise prior to diagnosis.  The majority of 
diabetic patients over the age of 65 have significant asymptomatic or symptomatic 
coronary artery disease, in which the development of autonomic neuropathy increases the 
incidence of silent ischemia (Coursin et al., 2004).  Diabetics with autonomic neuropathy 
have an increased risk of PONV and aspiration related to delayed gastric emptying.  
Aspiration is the leading cause of mortality in anesthesia prompting serious consideration 
and planning during the perioperative period (Robinson & Davidson, 2014). 
Independently, PONV is the second most common complaint occurring in 20 to 
40% of all surgical patients (Cao et al., 2017).  The occurrence of PONV can prolong 
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recovery, delay discharge, and result in unanticipated hospital admission (Shaikh et al., 
2016).  Diabetic patients already have increased rates of hospitalizations and 
complications; coupled with autonomic neuropathy contributing to PONV, a strategic 
plan must be implemented to provide the safest anesthetic.   
One of the most extensively used anti-emetics in the perioperative period is 
dexamethasone, a glucocorticoid.  The use of dexamethasone has been associated with 
potential risks including impaired wound healing, increased blood glucose levels, and an 
increase risk of infection (Miller et al., 2015).  These risk factors, combined with 
independent risk factors related to diabetes, make its use in the diabetic population 
controversial.   
The purpose of this systematic review was to examine the impact of 
dexamethasone on blood glucose levels in the adult diabetic surgical patient when used in 
the prevention of PONV.  A comprehensive literature review was completed using 
PubMed, Medline, CINAHL, and google scholar focusing on the pathology of diabetes 
and postoperative nausea and vomiting, and the pharmacology of dexamethasone.  The 
theoretical framework used for this systematic review was PRISMA, a four-phase 
flowchart compromised of 27-item checklist.  This checklist ensured an analytical and 
unbiased evaluation was made of each RCT (Moher et al., 2009). 
 Upon narrowing down the search results, individual study analysis was conducted 
on four studies that met the inclusion criteria.  Key information from each study was 
incorporated into individualized study data tables.  Data outcome tables were then 
developed to analyze the effect of dexamethasone on perioperative blood glucose of 
diabetic surgical patients.  Following, the Critical Appraisal Skills Programme (CASP) 
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checklist was used to appraise the individual RCTs.  Finally, a cross study analysis table 
was developed comparing the mean BG at 2 hours, 4 hours, 6 hours, 8 hours, and mean 
peak BG levels.  Diabetic patients receiving dexamethasone 8mg IV were compared to a 
diabetic control; a nondiabetic control; nondiabetic patients receiving dexamethasone 
8mg IV; nondiabetic and diabetic patients receiving ondansetron 4mg IV; and 
nondiabetic and diabetic patients receiving dexamethasone 4mg IV. 
 There were several limitations recognized when completing this systematic 
review.  Each study had a diabetic group that received dexamethasone 8mg IV which was 
used for comparison, however, the remaining groups all varied amongst the individual 
studies.  Three out of four studies had diabetic control groups with two of those studies 
also including nondiabetic control groups.  One study failed to have a control group, 
comparing BG levels with diabetic and nondiabetic patients who received a different 
antiemetic, ondansetron 4mg IV.  Only one of the studies was performed on patients who 
received the same surgical procedure, a laparoscopic Roux-en-Y gastric bypass.  Two of 
the other studies had varying surgical procedures under general anesthesia.  The final 
study was conducted under regional anesthesia.  All of the studies performed a standard 
preoperative BG assessment; however, the remaining intervals of assessment vary widely 
from study to study.  Another limitation for comparison is related to every study having a 
different value for what BG change is considered to be significant, ranging from 23mg/dl 
to 45mg/dl.  One study in particular had limited findings due to the use of insulin for any 
BG > 215mg/dl.  Also, one study infused a glucose (5%) and electrolyte infusion to all 
patients at a rate of 80ml/hr.  Lastly, none of the studies examined the incidence of 
complications related to hyperglycemia. 
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 The findings of this systematic review determined that in the adult diabetic 
surgical population, dexamethasone 8mg IV was associated with an increase in 
perioperative BG levels.  Although, the increase may not have been statistically 
significant. 
 Next, the recommendations and implications for advanced nursing practice will 
be presented.   
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Recommendations and Implications for Advanced Nursing Practice 
Diabetic surgical patients present with a variety of dynamic alterations in 
physiologic response.  Recognition and identification of patients with diabetes, 
particularly those with impaired glucose tolerance and associated pathologies, becomes 
imperative.  This is especially important as over a third of diabetic patients are 
undiagnosed, or untreated, when presenting for surgery (Vinik et al., 2003).  Anticipation 
of complications related to end-organ disease in the diabetic surgical patient is crucial for 
the anesthesia provider when constructing the anesthetic plan.  Perioperatively, diabetic 
patients have a two- to threefold increase in morbidity and mortality related to 
cardiovascular complications.  Much of the organ dysfunction can be related to diabetic 
autonomic neuropathy produced from diffuse damage to peripheral nerves and small 
vessels.  The widespread distribution of the autonomic nervous system (ANS) renders all 
organs susceptible to dysfunction (Vinik et al., 2003).   
Diabetic autonomic neuropathy first manifests in longer nerves.  The Vagus nerve 
is responsible for ~75% of all parasympathetic activity and is the longest nerve, resulting 
in early dysfunction.  Gastric emptying (gastroparesis) principally relies on vagal nerve 
function.  Approximately 50% of patients with chronic diabetes suffer from gastroparesis, 
increasing their perioperative risk for nausea and vomiting and also aspiration.  
Preoperative testing must be focused on identification and treating coexisting conditions 
to ensure patients are optimized in order to reduce the incidence of perioperative 
complications (Kadoi, 2010). 
Due to increased gastric dysfunction, diabetic patients require careful 
consideration when planning prophylaxis treatment of postoperative nausea and vomiting 
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(PONV).  Dexamethasone is one of the most common prophylactic medications used in 
the perioperative period for its antiemetic and analgesic effects.  The use of 
dexamethasone is, however, also associated with impaired wound healing and 
hyperglycemia, which are complications diabetic patients are already predisposed to 
(Godshaw et al., 2019).  A retrospective chart review completed by Godshaw et al. 
(2019) examined the use of dexamethasone in prevention of PONV and for analgesia in 
2,317 patients undergoing primary total hip or knee arthroplasty.  The primary outcome 
evaluated was the incidence of prosthetic joint infection (PJI).  Participants were 
principally divided into dexamethasone group and no dexamethasone group, and then 
further subdivided into diabetic and nondiabetic cohorts.  There were 428 diabetic 
patients in the dexamethasone group that received either 6mg or 12mg of IV 
dexamethasone preoperatively and 229 diabetics that were allocated in the no 
dexamethasone group.  A total of 25 (1.08%) PJIs were reported in the study, with 
diabetics having a significantly higher incidence of PJI in comparison to nondiabetics 
(2.59% versus 0.48%, p < 0.001).  There was no significant interaction between the use 
of dexamethasone and diabetic status (p = 0.646).  This suggests that the use of 
dexamethasone was not a contributory factor in the development of PJI (Godshaw et al., 
2019). 
This systematic review concluded that dexamethasone was associated with an 
increase in perioperative blood glucose levels, although a significant increase was not 
found among all studies.  The Society for Ambulatory Anesthesia suggests that for the 
well-controlled diabetic patient, intraoperative BG levels should be maintained <180 
mg/dL (10.0 mmol/L) and poorly controlled diabetics should be maintained around their 
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preoperative baseline (Joshi et al., 2010).  Chronic elevation of blood glucose levels in 
the diabetic patient should not be treated perioperatively with insulin due to altered 
counterregulatory responses leading to hypoglycemic symptoms at decreased and/or 
“normal” levels (Joshi et al., 2010).  Vigilance from the anesthesia provider is required in 
monitoring intraoperative blood glucose levels due to the detrimental effects of both hypo 
and hyperglycemia. 
The management of the diabetic patient during the perioperative period must be 
tailored to each individual patient.  Hyperglycemia and hypoglycemia are associated with 
increased morbidity and mortality; therefore, it is up to the anesthesia provider to monitor 
the patient’s blood glucose levels throughout the perioperative period in order to deter 
these complications (Joshi et al., 2010).  Despite widely available point of care blood 
glucose testing and the known incidence of hyperglycemia associated with 
dexamethasone use; blood glucose levels may not be commonly monitored after 
anesthesia.  A retrospective study completed by Sudlow et al. (2017) examined the 
incidence of subsequent measurement of blood glucose levels for 24-hours following 
anesthesia.  Out of 355 patients eligible for chart review, 243 (66%) received 
dexamethasone at a median dose of 6.7mg.  Only 16 patients (4.5%) received subsequent 
blood glucose assessments.  From these 16 patients, eight patients (50%) were diabetic 
and only two patients received additional blood glucose assessments within the 24-hour 
time period.  Three patients with diabetes developed wound infections with noted blood 
glucose levels ranging from 216 – 486 mg/dl within 24 hours postoperatively (Sudlow et 
al., 2017). 
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Individualization of the anesthetic plan is essential; the anesthesia provider must 
assess and evaluate the patient to allow for anticipation of potential complications.  
Although individualization is key, standardization of protocols, specifically, blood 
glucose assessments during the perioperative period allow for safer management of the 
diabetic patient.  This study concluded that dexamethasone does increase blood glucose 
levels after administration, therefore benefit versus harm must be weighed for each 
patient.  When choosing to use dexamethasone in the adult diabetic surgical population 
for prevention of PONV, the risk of an increased stress response, possibility of impaired 
wound healing, and increased risk of infection must be evaluated against the benefit of its 
antiemetic and analgesic properties.  Further research is needed to deduce whether a 
single dose of dexamethasone for prevention of PONV has any correlation with adverse 
outcomes such as surgical site infection or impaired wound healing.  Communication 
with the interdisciplinary teams caring for the patient is also important.  A handoff report 
to the PACU nurse, Advanced Practice Registered Nurse (APRN) and/or physician, 
summarizing your anesthetic plan and possible future implications is necessary to 
monitor for adverse outcomes.  Continued education amongst providers and care givers is 
necessary to promote the best possible outcomes while minimizing complications.  
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hours, and 24 hours. 
 
Group 1 –
dexamethasone 8mg IV 




A variety of surgical 
procedures were 
preformed and classified 





abdominal, or other. 




Group 3 – (n= 20) 




Group 4 – (n= 24) 
type 2 diabetics 
receiving 
ondansetron 
Group 2 – ondansetron 




dexamethasone 8mg IV 
at induction of 
anesthesia. 
 
Group 4 – ondansetron 








Study Specific Data 
Study 4: Purushothaman, A. M., Pujari, V. S., Kadirehally, N. B., Bevinaguddaiah, Y., & Reddy, P. R. (2018). A prospective randomized study 
on the impact of low-dose dexamethasone on perioperative blood glucose concentrations in diabetics and nondiabetics. Saudi Journal of 
Anesthesia, 12(2), 198-203. 
AIM/PURPOSE 
 
Investigate the effect of 
administering two low 
doses (4mg or 8mg) of 
dexamethasone on BG 
levels of diabetic and 
nondiabetic patients 
receiving spinal 






































18 – 70 years. 
 















Baseline capillary BG level 
was obtained immediately 
prior to administration of 
dexamethasone or control 
and reassessed every hour 
for 7 hours. A mean BG 
change of 23 mg/dl is to be 
considered clinically 
significant. The test drugs 
were reconstituted to a 
volume of 5mls and given 
immediately prior to 
delivery of spinal anesthetic. 
 
DM0 – 5ml normal saline 
 





A standardized spinal 
anesthetic was followed 
using aseptic technique -  
25-gauge Quincke needle 
delivering 0.5% 
hyperbaric bupivacaine 
15mg and buprenorphine 
60 mcg at either L2-L3 or 
L3-L4 midline approach. 
 
A total of 133 general 
surgeries, 24 gynecologic, 
and 43 orthopedic/plastic 
and other surgeries were 
included. 


































DM8 – dexamethasone 8mg 
IV 
ND0 – 5ml normal saline 
 
ND4 – dexamethasone 4mg 
IV 
 
ND8 – dexamethasone 8mg 
IV 
 
Note: DM – diabetic group, ND – nondiabetic group 
  





Outcome Data Collection 
 
Study 1: Nazar, C. E., Lacassie, H. J., López, R. A., & Muñoz, H. R. (2009). Dexamethasone for postoperative nausea and vomiting 
prophylaxis: Effect on glycaemia in obese patients with impaired glucose tolerance. European Journal of Anaesthesiology, 26, 318-321.  









BG (mg/dl) • 
p-value Significance 
Baseline 90.0 ± 10.8 88.2 ± 9.0  All BG samples measured after the beginning of 
surgery were higher 
compared to baseline in 
both groups.  Group 1, the 
dexamethasone group, 
exhibited higher BG levels 
from the 6th to the 12th hour 
after anesthesia compared to 
the control group.  
2 122.4 ± 28.8 129.6 ± 32.4 * 
4 147.6 ± 25.2 135.0 ± 18.0 * 
6 158.4 ± 18.0 126.0 ± 18.0 * † 
8 176.4 ± 25.2 129.6 ± 36.0 * † 
10 180.0 ± 32.4 127.8 ± 34.2 * † 
12 162.0 ± 21.6 122.4 ± 28.8 * † 
Maximum BG levels 187.2 ± 28.8 158.4 ± 30.6 < 0.05 
Note. (•) BG concentration converted to mg/dl with formula: mg/dl = 18 x mmol liter-1. (*) A p-value of less than 0.05 compared with 
baseline with the paired Student’s t-test. (†) A p-value of less than 0.05 between the groups with the unpaired Student’s t-test.   





Outcome Data Collection 
 
Study 2: Abdelmalak, B. B., Bonilla, A. M., Yang, D., Chowdary, H. T., Gottlieb, A., Lyden, S. P., & Sessler, D. I. (2013). The hyperglycemic 
response to major noncardiac surgery and the added effect of steroid administration in patients with and without diabetes. Anesthesia & Analgesia, 
115(5) 1116-1122 
BG sample times 
Group DM1 










Diabetic baseline BG 143.0 ± 53.0   
Mean maximal BG change 
did not change significantly 
between the DM and ND 
patients (p=0.39). 
Dexamethasone increased 
the mean maximal BG, 
change compared to control, 
in ND patients (p=0.0012); 
no hyperglycemic response 
to dexamethasone was seen 
in DM patients (p=0.99). 
Intraoperative maximal 
BG change 63.0 ± 66.0 63.0 ± 72.0 0 (-33, 33) 0.99 
Diabetic mean maximal 
BG change 63.0 ± 69  0.39 
Diabetics given insulin 
treatment intraoperatively 19 of 49 (39%)  <0.001 
Note. DM – diabetic group, ND – nondiabetic group, CI – confidence interval. (a) Linear regression model incorporating factors for 
placebo vs dexamethasone and DM vs ND; the interaction between DM and dexamethasone was significant (p= 0.094, less than 
criterion of p< 0.10); Bonferroni correction was used for two comparisons (a = 0.05/2 = 0.025). 
  




Outcome Data Collection 
Study 2: Abdelmalak, B. B., Bonilla, A. M., Yang, D., Chowdary, H. T., Gottlieb, A., Lyden, S. P., & Sessler, D. I. (2013). The hyperglycemic 
response to major noncardiac surgery and the added effect of steroid administration in patients with and without diabetes. Anesthesia & 















baseline BG 96.0 ± 19.0   
Mean maximal BG change did not 
change significantly between the 
DM and ND patients (p=0.39). 
Dexamethasone increased the mean 
maximal BG, change compared to 
control in ND patients (p=0.0012); 
no hyperglycemic response to 














8 of 136 (6%)  <0.001 
Note: DM – diabetic group, ND – nondiabetic group, CI – confidence interval. (a) Linear regression model incorporating factors for 
placebo vs dexamethasone and DM vs ND; the interaction between DM and dexamethasone was significant (p= 0.094, less than 
criterion of p< 0.10); Bonferroni correction was used for two comparisons (a = 0.05/2 = 0.025). 
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Table B-3 
Outcome Data Collection 
Study 3: Tien, M., Gan, T. J., Dhakal, I., White, W. D., Olufolabi, A. J., Fink, R., Mishriky, B. M., Lacassie, H. J., & Habib, A. S. (2016). The 
effect of anti-emetic doses of dexamethasone on postoperative blood glucose levels in non-diabetic and diabetic patients: A prospective 







BG (mg/dl) • 




BG (mg/dl) • 
p-value 
Group 3 
type 2 diabetics 
dexamethasone 
(n=20) 
BG (mg/dl) • 
Group 4 
type 2 diabetics 
ondansetron 
(n=24) 
BG (mg/dl) • 
p-value Significance 
0 h 95.4 ± 16.2 91.8 ± 14.4 0.62 124.2 ± 28.8 129.6 ± 34.2 0.59 In non-diabetic patients, the maximum 
BG was higher in those 
who received 
dexamethasone 
compared to those who 
received ondansetron (p 
= 0.04); the same 
conclusion was 
exhibited with type 2 
diabetic patients who 
received 
dexamethasone 
compared to those who 
received ondansetron (p 
< 0.01) 
2 h 115.2 ± 18.0 118.8 ± 23.4 0.65 169.2 ± 50.4 145.8 ± 39.6 0.10 
4 h 153.0 ± 28.8 131.4 ± 28.8 0.02 187.2 ± 54.0 154.8 ± 37.8 0.08 
24 h 126.0 ± 45.0 1170 ± 18.0 0.99 176.4 ± 45.0 149.4 ± 41.4 0.05 
Mean Peak BG 163.8 ± 39.6 140.4 ± 25.2 0.04 252.0 ± 45.0 192.6 ± 43.2 <0.01 
Maximum 4-h 
BG change 57.6 ± 30.6 41.4 ± 30.6 0.10 66.6 ± 48.6 28.8 ± 37.8 <0.01 
Maximum 24-h 
BG change 68.4 ± 43.2 48.6 ± 30.6 0.09 126.0 ± 37.8 63.0 ± 39.6 <0.01 
Maximum 24-h 
BG >180 6 (30%) 2 (10%) 0.13 19 (95%) 12 (50%) <0.01 
Note. (•) BG concentration converted to mg/dl with formula: mg/dl = 18 x mmol liter-1.  
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Table B-4.1 
Outcome Data Collection 
Study 4: Purushothaman, A. M., Pujari, V. S., Kadirehally, N. B., Bevinaguddaiah, Y., & Reddy, P. R. (2018). A prospective randomized study 
on the impact of low-dose dexamethasone on perioperative blood glucose concentrations in diabetics and nondiabetics. Saudi Journal of 
Anesthesia, 12(2), 198-203. 
BG sample 
times 
Group 1 – 
DM0(n=30) 
BG (mg/dl) 
Group 2 – DM4 
(n=30) 
BG (mg/dl) 




T0 134.4 ± 22.8 125.6 ± 21.0 125.8 ± 22.6 0.219 There was a rise in BG levels in both diabetic and nondiabetic groups who 
received dexamethasone. However, 
this rise was not clinically significant 
with a range of 10-15 mg/dl from 
baseline. BG levels peaked at T4 in 
the DM4 group, which was a 
statistically significant increase from 
baseline. BG levels in the DM8 group 
peaked at T5.  
T1 139.3 ± 24.5 137.7 ± 20.0 135.6 ± 26.1 0.835 
T2 141.2 ± 25.4 149.3 ± 20.6 143.3 ± 28.0 0.426 
T3 138.5 ± 26.0 161.3 ± 20.5 154.2 ± 34.2 0.006*,†,‡ 
T4 147.3 ± 23.6 169.3 ± 21.8 166.8 ± 25.9 <0.001*,†,‡ 
T5 144.4 ± 22.9 165.0 ± 21.4 167.5 ± 18.6 <0.001*,†,‡ 
T6 146.9 ± 20.8 158.0 ± 25.4 160.2 ± 16.0 <0.037*,†,‡ 
T8 144.5 ± 20.6 151.2 ± 20.8 149.1 ± 17.0 0.401 
Mean Peak BG 148.0 ± 17.2 169.0 ± 17.3 168.0 ± 22.4  
Note. (*) Indicates p-value < 0.05 significant between the three groups by analysis of variance. Post hoc analysis between the groups 
was done. (†) Indicates p-value < 0.05 significant between DM0 and DM4. (‡) Indicates p-value < 0.05 significant between DM0 and 
DM8. T0 (baseline), T1 (60), T2 (120), T3 (180), T4 (240), T5 (300), T6 (360), and T8 (480) minutes after test drug administration. 
DM: Diabetes group. DM0: control group, DM4: 4mg dexamethasone IV, DM8: 8mg dexamethasone IV.  
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Table B-4.2 
Outcome Data Collection 
Study 4: Purushothaman, A. M., Pujari, V. S., Kadirehally, N. B., Bevinaguddaiah, Y., & Reddy, P. R. (2018). A prospective randomized study 
on the impact of low-dose dexamethasone on perioperative blood glucose concentrations in diabetics and nondiabetics. Saudi Journal of 
Anesthesia, 12(2), 198-203. 
BG sample 
times 















T0 96.3 ± 11.3 93.3 ± 11.6 95.5 ± 15.5 0.654 There was a rise in BG levels in both 
diabetic and nondiabetic groups who 
received dexamethasone. However, this rise 
was not clinically significant with a range of 
10-15 mg/dl from baseline. BG levels 
peaked in the ND4 and ND8 groups at T5 
and T6, respectively. At T8, in comparison 
with the DM8 group, the ND8 group had a 
statistically significant increase in BG levels. 
T1 99.7 ± 12.3 98.4 ± 14.8 98.5 ± 13.8 0.918 
T2 102.1 ± 13.4 104.9 ± 18.9 104.8 ± 15.3 0.739 
T3 104.9 ± 15.1 114.9 ± 19.3 116.9 ± 21.2 0.034*,‡ 
T4 100.9 ± 23.7 126.6 ± 23.3 129.4 ± 25.3 <0.001*,†,‡ 
T5 103.1 ± 24.5 133.1 ± 26.1 137.8 ± 23.8 <0.001*,†,‡ 
T6 103.7 ± 15.3 124.3 ± 24.5 139.9 ± 27.9 <0.001*,†,‡,§ 
T8 100.3 ± 15.0 114.6 ± 21.3 131.1 ± 28.1 <0.001*,†,‡,§ 
Mean Peak BG 105.0 ± 23.6 133.0 ± 20.4 140.0 ± 23.2  
Note. (*) Indicates p-value < 0.05 significant between the three groups by analysis of variance. Post hocanalysis between the groups was done. (†) 
Indicates p-value < 0.05 significant between ND0 and ND4. (‡) Indicated p-value < 0.05 significant between ND0 and ND8. (§) Indicates p-value < 
0.05 significant between ND4 and ND8. T0 (baseline), T1 (60), T2 (120), T3 (180), T4 (240), T5 (300), T6 (360), and T8 (480) minutes after test 







Table C-1  
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
Note. (*) The study did not examine differences or complications in outcomes between 
the two groups related to hyperglycemia, unable to determine. 
  
Study 1: Nazar, C. E., Lacassie, H. J., López, R. A., & Muñoz, H. R. (2009). Dexamethasone 
for postoperative nausea and vomiting prophylaxis: Effect on glycaemia in obese patients with 
impaired glucose tolerance. European Journal of Anaesthesiology, 26, 318-321. 
A) Are the results of the trial valid? Yes Can’t tell No 
1. Did the trial address a clearly focused 
issue? 
X   
2. Was the assignment of patients to 
treatments randomized? 
X   
3. Were all of the patients who entered the 
trial properly accounted for at its conclusion? 
X   
4. Were patients, health workers, and study 
personnel “bind” to treatment? 
X   
5. Were the groups similar at the start of the 
trial? 
X   
6. Aside from the experimental intervention, 
were the groups treated equally? 
X   
B) What are the results?    
7. How large was the treatment effect? All BG samples measured after the 
beginning of surgery were higher 
compared to baseline in both groups.   
8. How precise was the estimate of the 
treatment effect? 
Group 1, the dexamethasone group, 
exhibited higher BG levels from the 6th to 
the 12th hour after anesthesia compared to 
the control group. 
C) Will the results help locally? Yes Can’t tell No 
9. Can the results be applied in your context? X   
10. Were all clinically important outcomes 
considered? 
 X*  
11. Are the benefits worth the harms and 
costs? 
 X*  
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Table C-2 
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
Study 2: Abdelmalak, B. B., Bonilla, A. M., Yang, D., Chowdary, H. T., Gottlieb, A., Lyden, 
S. P., & Sessler, D. I. (2013). The hyperglycemic response to major noncardiac surgery and the 
added effect of steroid administration in patients with and without diabetes. Anesthesia & 
Analgesia, 115(5) 1116-1122 
A) Are the results of the trial valid? Yes Can’t tell No 
1. Did the trial address a clearly focused 
issue? 
X   
2. Was the assignment of patients to 
treatments randomized? 
X   
3. Were all of the patients who entered the 
trial properly accounted for at its conclusion? 
X   
4. Were patients, health workers, and study 
personnel “bind” to treatment? 
X   
5. Were the groups similar at the start of the 
trial? 
  X† 
6. Aside from the experimental intervention, 
were the groups treated equally? 
  X‡ 
B) What are the results?    
7. How large was the treatment effect? Mean maximal BG change did not change 
significantly between the DM and ND 
patients (p=0.39).  
8. How precise was the estimate of the 
treatment effect? 
Dexamethasone increased the mean 
maximal BG, change compared to 
control, in ND patients (p=0.0012); no 
hyperglycemic response to 
dexamethasone was seen in DM patients 
(p=0.99). 
C) Will the results help locally? Yes Can’t tell No 
9. Can the results be applied in your 
context? 
X   
10. Were all clinically important outcomes 
considered? 
 X*  
11. Are the benefits worth the harms and 
costs? 
 X*  
Note. (†) Patients selected for the study were diabetic and non-diabetic, of varying 
age, and received various types of surgery. (‡) Patients received insulin for BG levels > 
215 mg/dl to maintain BG in the target range 180 to 200 mg/dl (*) The study did not 
examine differences or complications in outcomes between the two groups related to 
hyperglycemia, unable to determine. 
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Table C-3 
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
Study 3: Tien, M., Gan, T. J., Dhakal, I., White, W. D., Olufolabi, A. J., Fink, R., Mishriky, B. 
M., Lacassie, H. J., & Habib, A. S. (2016). The effect of anti-emetic doses of dexamethasone 
on postoperative blood glucose levels in non-diabetic and diabetic patients: A prospective 
randomized controlled study. Anaesthesia, 71, 1037-1043. 
A) Are the results of the trial valid? Yes Can’t tell No 
1. Did the trial address a clearly focused 
issue? 
X   
2. Was the assignment of patients to 
treatments randomized? 
X   
3. Were all of the patients who entered the 
trial properly accounted for at its conclusion? 
  X† 
4. Were patients, health workers, and study 
personnel “bind” to treatment? 
X   
5. Were the groups similar at the start of the 
trial? 
  X‡ 
6. Aside from the experimental 
intervention, were the groups treated equally? 
  X†† 
B) What are the results?    
7. How large was the treatment effect? Multiple variate analysis illustrated that 
use of dexamethasone was a significant 
predictor of maximum postoperative BG 
increase (p < 0.01). 
8. How precise was the estimate of the 
treatment effect? 
In non-diabetic patients, the maximum BG 
was higher in those who received 
dexamethasone compared to those who 
received ondansetron (p = 0.04); the same 
conclusion was exhibited with type 2 
diabetic patients who received 
dexamethasone compared to those who 
received ondansetron (p < 0.01). 
C) Will the results help locally? Yes Can’t tell No 
9. Can the results be applied in your 
context? 
X   
10. Were all clinically important outcomes 
considered? 
 X*  
11. Are the benefits worth the harms and 
costs? 
 X*  
Note. (†) Three out of 88 patients were discharged early from the hospital and considered 
lost to follow-up. (‡) Patients selected for the study were diabetic and non-diabetic, of 
varying age, and received various types of surgery. (††) Diabetic patients received insulin 
subcutaneously for BG levels > 200 mg/dl. (*) The study did not examine differences or 
complications in outcomes between the two groups related to hyperglycemia, unable to 
determine. 
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Table C-4  
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
Note: (‡) Patients selected for the study were diabetic and non-diabetic, of varying age, 
and received various types of surgery. (*) The study did not examine differences or 
complications in outcomes between the two groups related to hyperglycemia, unable to 
determine. 
 
Study 4: Purushothaman, A. M., Pujari, V. S., Kadirehally, N. B., Bevinaguddaiah, Y., & 
Reddy, P. R. (2018). A prospective randomized study on the impact of low-dose 
dexamethasone on perioperative blood glucose concentrations in diabetics and nondiabetics. 
Saudi Journal of Anesthesia, 12(2), 198-203. 
A) Are the results of the trial valid? Yes Can’t tell No 
1. Did the trial address a clearly focused 
issue? 
X   
2. Was the assignment of patients to 
treatments randomized? 
X   
3. Were all of the patients who entered the 
trial properly accounted for at its conclusion? 
X   
4. Were patients, health workers, and study 
personnel “bind” to treatment? 
X   
5. Were the groups similar at the start of the 
trial? 
  X‡ 
6. Aside from the experimental intervention, 
were the groups treated equally? 
X   
B) What are the results?    
7. How large was the treatment effect? There was a rise in BG levels in both 
diabetic and nondiabetic groups who 
received dexamethasone. However, this 
rise was not clinically significant with a 
range of 10-15 mg/dl from baseline.  
8. How precise was the estimate of the 
treatment effect? 
BG levels peaked at T4 in the DM4 group, 
which was a statistically significant 
increase from baseline. BG levels in the 
DM8 group peaked at T5.  BG levels 
peaked in the ND4 and ND8 groups at T5 
and T6, respectively. At T8, in 
comparison with the DM8 group, the ND8 
group had a statistically significant 
increase in BG levels. 
C) Will the results help locally? Yes Can’t tell No 
9. Can the results be applied in your 
context? 
X   
10. Were all clinically important outcomes 
considered? 
 X*  
11. Are the benefits worth the harms and 
costs? 







Cross Study Analysis 










Study 1  





All BG samples measured 
after the beginning of surgery 
were higher compared to 
baseline in both groups.  
Group 1 exhibited higher BG 
levels from the 6th to the 12th 
hour after anesthesia 
compared to the control 
group.   
122.4 ± 28.8 147.6 ± 25.2 158.4 ± 18.0 176.4 ± 25.2 187.2 ± 28.8 
Group 2- 







Mean maximal BG change 
did not change significantly 
between the DM and ND 
patients (p=0.39). 
Dexamethasone increased the 
mean maximal BG, change 
compared to control in ND 
patients (p=0.0012); no 
hyperglycemic response to 
dexamethasone was seen in 
DM patients (p=0.99). 
n/a n/a n/a n/a 209.0 ± 66.0 
Group 2-DM2 
control n/a n/a n/a n/a 209.0 ± 72.0 
Group 3- ND1 
dexamethasone 
8mg IV 
n/a n/a n/a n/a 182.0 ± 41.0 
Group 4- ND2 
control n/a n/a n/a n/a 154.0 ± 45.0 
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Study 3  
(Tien et al., 
2016) 
Group 1- ND 
dexamethasone 
8mg IV 
In non-diabetic patients, the 
maximum BG was higher in 
those who received 
dexamethasone compared to 
those who received 
ondansetron (p = 0.04); the 
same conclusion was 
exhibited with type 2 diabetic 
patients who received 
dexamethasone compared to 
those who received 
ondansetron (p < 0.01) 
115.2 ± 18.0 153.0 ± 28.8 n/a n/a 163.8 ± 39.6 
Group 2- ND 
ondansetron 
4mg IV 
118.8 ± 23.4 131.4 ± 28.8 n/a n/a 140.4 ± 25.2 
Group 3- DM 
dexamethasone 
8mg IV 
169.2 ± 50.4 187.2 ± 54.0 n/a n/a 252.0 ± 45.0 
Group 4- DM 
ondansetron 
4mg IV 
145.8 ± 39.6 154.8 ± 37.8 n/a n/a 192.6 ± 43.2 
Study 4 
(Purushothaman 
et al., 2018) 
Group 1- DM 
control 
There was a rise in BG levels 
in both diabetic and 
nondiabetic groups who 
received dexamethasone. 
However, this rise was not 
clinically significant with a 
range of 10-15 mg/dl from 
baseline. BG levels peaked at 
T4 in the DM4 group, which 
was a statistically significant 
increase from baseline. BG 
levels in the DM8 group 
peaked at T5.  BG levels 
141.2 ± 25.2 147.3 ± 23.6 146.9 ± 20.8 144.5 ± 20.6 148.0 ± 17.2 
Group 2- DM 
dexamethasone 
4mg IV 
149.3 ± 20.6 169.3 ± 21.8 158.0 ± 25.4 151.2 ± 20.8 169.0 ± 17.3 
Group 3- DM 
dexamethasone 
8mg IV 
143.3 ± 28.0 166.8 ± 26.0 160.2 ± 16.0 149.1 ± 17.0 168.0 ± 22.4 
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Group 4- ND 
control 
peaked for groups ND4 and 
ND8 at T5 and T6, 
respectively. At T8, in 
comparison with the DM8 
group, the ND8 group had a 
statistically significant 
increase in BG levels. 
102.1 ± 13.4 100.9 ± 23.7 103.7 ± 15.3 100.3 ± 15.0 105.0 ± 23.6 
Group 5- ND 
dexamethasone 
4mg IV 
104.9 ± 18.9 126.6 ± 23.3 124.3 ± 24.5 114.6 ± 21.3 133.0 ± 20.4 
Group 6- ND 
dexamethasone 
8mg IV 
104.8 ± 15.3 129.4 ± 25.3 139.9 ± 27.9 131.1 ± 28.1 140.0 ± 23.2 
Note. DM – diabetic group, ND – nondiabetic group. BG = mg/dl 
